The groundbreaking rise of Viagra has long been a benchmark of pharmaceutical success, but its position within the broader industry now triggers questions about future yields . Generic versions are undercutting exclusivity , causing worries that betting on companies significantly dependent to Viagra's former influence could be a dangerous decision